MolNFT v1 · #26336 · protein
Ppargamma in complex with a 2-baba compound
1WM0 · Peroxisome proliferator activated receptor gamma: “Ppargamma in complex with a 2-baba compound”. X-ray diffraction, 1 ligand (PLB), 1 pocket (best druggability 0.85). MolNFT v1 #26336 on GenesisL1: 3D structure, binding sites and…
- PDB
- 1WM0
- Type
- protein
- Length
- 282 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Peroxisome proliferator activated receptor gamma; 14-mer from nuclear receptor…
- UniProt
- Q96J12, Q61026
- Ligands
- PLB
- Pockets
- 1 · best druggability 0.85
Structure
x-ray diffraction · 2 distinct chains · 61% helix, 5% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| X | Peroxisome proliferator activated receptor gamma | protein | 272 | 61% helix, 5% strand | Q96J12 |
| Y | 14-mer from nuclear receptor coactivator 2 | protein | 10 | 60% helix, 0% strand | Q61026 |
Ligands and binding sites
- PLB · 2-[(2,4-dichlorobenzoyl)amino]-5-(pyrimidin-2-yloxy)benzoic acid · ligand · chains X
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 353 | 0.85 | 0.94 | 52 | PLB |
Interfaces
1 interface between chains.
- X–Y · 572 Ų buried · 6 hydrogen bonds · protein-protein
Compared structures
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q96J12
- Every structure of UniProt Q61026
- Elsewhere: RCSB PDB 1WM0 · PDBe 1WM0 · UniProt Q96J12 · UniProt Q61026
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.